医学
淀粉样变性
周围神经病变
淀粉样变性
内科学
淀粉样蛋白(真菌学)
不确定意义的单克隆抗体病
肌病
病理
胃肠病学
免疫学
免疫球蛋白轻链
单克隆
内分泌学
抗体
单克隆抗体
糖尿病
作者
Andreas Thimm,Alexander Carpinteiro,Sara Oubari,Μαρία Παπαθανασίου,Peter Luedike,Lukas Kessler,Christoph Rischpler,Tobias Blau,Hans Christian Reinhardt,Tienush Rassaf,Hartmut Schmidt,Christoph Kleinschnitz,Tim Hagenacker
标识
DOI:10.1016/j.jns.2022.120341
摘要
Immunoglobulin light chain (AL) amyloidosis is a life-threatening systemic disease due to plasma cell dyscrasias, which is characterized by amyloid deposition in various tissues. Neurological manifestations, in particular peripheral nervous system involvement, play a major role for quality of life and treatment decisions as frequently potentially neurotoxic drugs are used.We retrospectively investigated the prevalence of neurological manifestations, its risk factors and prognostic value in 155 consecutive patients with AL amyloidosis in a single German tertiary center between 2010 and 2021. Multiple logistic regression was performed to identify predictors of amyloid neuropathy and the impact of peripheral neuropathy on patient survival was assessed by Cox proportional hazard regression analysis.Nearly half of patients showed at least one of four neurological manifestations of AL amyloidosis which were frequent in our study: peripheral neuropathy (36.8%), carpal tunnel syndrome (12.9%), lumbar spinal stenosis (7.1%), and amyloid myopathy (3.9%). Male sex (OR 2.943, CI 1.152-8.139, p = 0.029) and cardiac involvement (OR 6.186, CI 1.449-43.38, p = 0.028) were independent predictors of peripheral neuropathy which was closely related to autonomic dysfunction in patients with AL amyloidosis. Peripheral neuropathy had no impact on survival (HR 0.952, CI 0.517-1.754, p = 0.876).Neurological involvement is common in systemic AL amyloidosis. Treatment decisions should take into account peripheral neuropathy, in particular in male patients with amyloid cardiomyopathy, but also amyloid myopathy that seems to be not as rare as previously suggested.
科研通智能强力驱动
Strongly Powered by AbleSci AI